Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
Status:
Terminated
Trial end date:
2021-06-15
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of zilucoplan in patients
with Immune-Mediated Necrotizing Myopathy (IMNM). Subjects will be randomized in a 1:1 ratio
to receive daily SC doses of 0.3 mg/kg zilucoplan or matching placebo for 8 weeks.